Amplia Therapeutics Limited (ASX:ATX)

Revenue by Segment

Financials in millions AUD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Biopharmaceutical Sector	4.79M	3.78M	4.45M	1.19M	1.98M
Biopharmaceutical Sector Growth	26.63%	-15.03%	274.34%	-40.03%	29.33%
Total	4.79M	3.78M	4.45M	1.19M	1.98M
Total Growth	26.63%	-15.03%	274.34%	-40.03%	29.33%

Revenue by Geography

Financials in millions AUD. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Australia	4.79M	3.78M	4.45M	1.19M	1.98M
Australia Growth	26.63%	-15.03%	274.34%	-40.03%	29.33%
Total	4.79M	3.78M	4.45M	1.19M	1.98M
Total Growth	26.63%	-15.03%	274.34%	-40.03%	29.33%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 20, 2026

Data Sources Report a data error